BCMA CAR-NK (Shenzhen Pregene Biopharma) vs SENL103

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Shenzhen Pregene Biopharma)

Developed by Shenzhen Pregene Biopharma Co., Ltd.

Phase 1/2 in Multiple Myelomaallogeneic CAR-NK cell therapy
Weak signal

NCT05652530 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.

No aligned efficacy figure on record for this race.

SENL103

Developed by Hebei Senlang Biotechnology

Phase 1/2 in Multiple Myelomacell therapy (CAR-T)
Weak signal

NCT06067581 · Phase 1 · status unknown

This is a small, uncontrolled, open-label Phase 1 dose-escalation study with no comparator arm, designed to find a safe dose of SENL103 CAR-T therapy in heavily pretreated myeloma patients. Efficacy is only a secondary measure and no results have been posted, so there is no evidence yet of a clinical effect.

Next expected readout: February 2028 · NCT07421856 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCMA CAR-NK (Shenzhen Pregene Biopharma)SENL103
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
SENL103
—Not reported

OS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
SENL103
—Not reported

ORR

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
SENL103
—Not reported

VGPR or better

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
SENL103
—Not reported

MRD negativity

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
SENL103
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.

SENL103: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · SENL103's landscape